Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NYMOX PHARMACEUTICAL CORPORATION

(NYMX)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nymox Pharmaceutical : Expects to File for Fexapotide Triflutate Marketing Approval to Treat Benign Prostatic Hyperplasia by September

05/06/2021 | 02:51pm EDT


ę MT Newswires 2021
All news about NYMOX PHARMACEUTICAL CORPORATION
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 2000 Value Ind..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell Small Cap Comp..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000 Value Ind..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000 Index
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000E Growth I..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 2500 Growth In..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000E Index
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 2000 Index
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000 Growth In..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell Small Cap Comp..
CI
More news
Financials (USD)
Sales 2020 0,01 M - -
Net income 2020 -11,7 M - -
Net cash 2020 3,19 M - -
P/E ratio 2020 -15,6x
Yield 2020 -
Capitalization 131 M 131 M -
EV / Sales 2019 1 283x
EV / Sales 2020 37 731x
Nbr of Employees -
Free-Float 55,0%
Chart NYMOX PHARMACEUTICAL CORPORATION
Duration : Period :
Nymox Pharmaceutical Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NYMOX PHARMACEUTICAL CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Paul Averback Chairman, President & Chief Executive Officer
Erik Danielsen Chief Financial Officer
Randall J. Lanham COO, Secretary, Director & General Counsel
David S. Morse Independent Director
James G. Robinson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NYMOX PHARMACEUTICAL CORPORATION-35.89%131
MODERNA, INC.231.78%139 174
LONZA GROUP AG25.60%58 688
IQVIA HOLDINGS INC.38.03%47 386
CELLTRION, INC.-26.60%31 285
SEAGEN INC.-11.93%28 062